Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
UNII J06Y7MXW4D
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoacusis04.02.01.006--
Retinal toxicity12.03.01.036; 06.09.03.013--Not Available
Osteopenia15.02.03.003; 14.04.04.0040.001239%Not Available
Pneumomediastinum22.09.03.0040.001239%Not Available
Eschar24.04.03.024; 23.03.03.027; 12.01.08.008--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Infusion site pain08.02.05.014; 12.07.05.0020.004213%Not Available
Growth retardation15.03.05.016; 14.03.02.031; 05.03.02.007--
Transaminases increased13.03.04.036--Not Available
Angiopathy24.03.02.007--Not Available
Induration08.01.03.020--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder15.06.01.006; 10.04.04.026--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
Renal injury20.01.03.015; 12.01.05.001--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.003098%
Drug intolerance08.06.01.0130.001859%Not Available
Knee deformity15.10.03.0020.001859%Not Available
Renal impairment20.01.03.0100.001239%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.001859%
Iron overload14.13.03.002; 12.02.08.0050.001859%
Metaphyseal dysplasia03.11.06.006; 15.11.06.006--Not Available
Liver injury12.01.17.012; 09.01.07.0220.001239%Not Available
Acute kidney injury20.01.03.016--
Multiple organ dysfunction syndrome08.01.03.0570.001859%
Concomitant disease aggravated08.01.03.0630.001239%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages